170 related articles for article (PubMed ID: 24388410)
21. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
22. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
23. Taming vessels to treat cancer.
Jain RK
Sci Am; 2008 Jan; 298(1):56-63. PubMed ID: 18225696
[No Abstract] [Full Text] [Related]
24. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
25. [Adjuvant bevacizumab and cetuximab for stage III colon cancer: why such failure in an adjuvant situation?].
André T; Larsen AK; de Gramont A
Bull Cancer; 2012 Jun; 99(6):607-8. PubMed ID: 22900267
[No Abstract] [Full Text] [Related]
26. [Molecular target therapy for colonic neoplasms].
Oki E; Ota M; Honbo T; Egashira A; Tokunaga E; Sadanaga N; Morita M; Kakeji Y; Maehara Y
Nihon Naika Gakkai Zasshi; 2007 Feb; 96(2):289-94. PubMed ID: 17370595
[No Abstract] [Full Text] [Related]
27. Bevacizumab: one treatment for all the seasons?
Gelibter AJ; Di Segni S; Zeuli M; Cognetti F
J Clin Oncol; 2008 Jan; 26(3):511; author reply 511-2. PubMed ID: 18202430
[No Abstract] [Full Text] [Related]
28. Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.
You B; Chen EX
J Clin Pharmacol; 2012 Feb; 52(2):128-55. PubMed ID: 21427284
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
30. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
31. [Anti-angiogenetic agents for solid tumors].
Blay JY
Rev Med Interne; 2007 Jun; 28 Suppl 1():S7-8. PubMed ID: 17482319
[No Abstract] [Full Text] [Related]
32. Bevacizumab beyond progression: does this make sense?
Ellis LM; Haller DG
J Clin Oncol; 2008 Nov; 26(33):5313-5. PubMed ID: 18854567
[No Abstract] [Full Text] [Related]
33. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar A; Tan CR; Annamalai A; Tuli R
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
[TBL] [Abstract][Full Text] [Related]
34. [PZ Innovation Prize for Avastin: Bevacizumab--new therapy option in colon carcinoma].
Krankenpfl J; 2005; 43(7-10):234. PubMed ID: 16515304
[No Abstract] [Full Text] [Related]
35. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
36. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
37. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
Cohen DJ; Hochster HS
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S21-7. PubMed ID: 18361803
[TBL] [Abstract][Full Text] [Related]
38. Targeted biotherapy in metastatic colorectal carcinoma: Current practice.
Cacheux W; Le Tourneau C; Baranger B; Mignot L; Mariani P
J Visc Surg; 2011 Feb; 148(1):12-8. PubMed ID: 21277276
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Köhne CH; Lenz HJ
Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
[TBL] [Abstract][Full Text] [Related]
40. [Interpretation of the updates of NCCN 2017 version 1.0 guideline for colorectal cancer].
Chen G
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jan; 20(1):28-33. PubMed ID: 28105616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
